Even though RU486 can bind to AR and PR in addition to GR (Kach et al. 2017), a combination therapy with RU486 and ENZ is under evaluation in clinical trials in hormone-resistant PCa (NCT02012296). Here, NR3C1 is linked to posterior cortical atrophy.